Definium Therapeutics has announced positive outcomes from its Phase 3 trial of an LSD-based therapy aimed at treating major depression.
This trial represents a crucial advancement in the development of psychedelic drugs for mental health treatment.
As interest in psychedelic therapies grows, this study could pave the way for future regulatory approvals and expanded treatment options.